{"product_id":"prostate-cancer-detection-and-treatment-a-new-approach-for-patients","title":"Prostate Cancer Detection and Treatment: A New Approach for Patients","description":"\u003cp\u003eProstate cancer is the most common cancer in men, with approximately 75,000 new diagnoses each year in Germany alone. This article explains a major shift in how doctors now approach prostate cancer — from who gets screened and how, to which patients truly need treatment. New guidelines recommend a personalized, risk-adapted approach: measuring a baseline PSA level at age 45, using MRI to avoid unnecessary biopsies, and expanding active surveillance to more low-risk patients. For patients, this means fewer unnecessary procedures and side effects, while still catching dangerous cancers early.\u003c\/p\u003e\n\n\u003ch1\u003eProstate Cancer Detection and Treatment: A New Approach for Patients\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eWhy This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#early-detection\"\u003eRisk-Adapted Early Detection: The New PSA Strategy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#dre\"\u003eDigital Rectal Examination: What Has Changed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#psa-mri\"\u003eThe New PSA-MRI Diagnostic Algorithm\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#biopsy\"\u003eProstate Biopsy Techniques\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#psma-pet\"\u003ePSMA-PET\/CT Imaging\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#genetic\"\u003eGenetic Counseling and Testing\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#treatment\"\u003eTreatment of Localized Prostate Cancer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#active-surveillance\"\u003eActive Surveillance: Monitoring Instead of Surgery\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#surgery-radiation\"\u003eSurgery and Radiation Therapy\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eA baseline PSA at age 45 personalizes screening; most men need no repeat test for 5 years.\u003c\/li\u003e\n\u003cli\u003eProstate MRI before biopsy avoids up to 70% of invasive biopsies and doubles cancer detection accuracy.\u003c\/li\u003e\n\u003cli\u003eLow-risk prostate cancer (ISUP grade group 1) should be managed with active surveillance, not immediate surgery or radiation.\u003c\/li\u003e\n\u003cli\u003eIn the ProtecT trial, 15-year cancer-specific survival exceeded 97% for surgery, radiation, or active monitoring.\u003c\/li\u003e\n\u003cli\u003ePSMA-PET\/CT is significantly more accurate than CT with bone scan for staging lymph node metastases (92% vs 65%).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eWhy This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer is the most commonly diagnosed type of cancer in men in Germany, and the second most common cause of cancer-related deaths — behind only lung cancer and ahead of colorectal cancer. In 2022, approximately \u003cstrong\u003e75,000 new cases\u003c\/strong\u003e were diagnosed. About \u003cstrong\u003e10-15% of all men\u003c\/strong\u003e will receive a prostate cancer diagnosis at some point during their lifetime.\u003c\/p\u003e\n\n\u003cp\u003eThe good news: the 5-year survival rate is approximately \u003cstrong\u003e90%\u003c\/strong\u003e. Three-quarters of all tumors are detected at an early stage (T1 or T2), meaning they are still confined to the prostate. Prostate cancer is more common in older men, with an average age at diagnosis of \u003cstrong\u003e71 years\u003c\/strong\u003e (as of 2021).\u003c\/p\u003e\n\n\u003cp\u003eHowever, there's a critical problem hiding in those statistics. \u003cstrong\u003eHalf of all diagnosed prostate cancers\u003c\/strong\u003e are what doctors call \"latent\" — they are undetected, clinically indolent tumors that would never cause symptoms or shorten a man's life. The dilemma facing medicine is that as prostate cancer becomes more common, it becomes increasingly important to distinguish these harmless tumors from aggressive ones that can spread (metastasize) — and to make that distinction as early as possible.\u003c\/p\u003e\n\n\u003cp\u003eThe challenge of \"overdiagnosis\" is significant. Currently, for every man who is saved from dying of prostate cancer by early detection, \u003cstrong\u003e14 men\u003c\/strong\u003e receive a cancer diagnosis that is unnecessary in every respect, and some of them are treated for cancer as well. Looking ahead, the number of new prostate cancer cases worldwide is expected to \u003cstrong\u003edouble\u003c\/strong\u003e over the next 20 years due to the aging population, while deaths are projected to rise by \u003cstrong\u003e85%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe concept of overdiagnosis can't be completely eliminated because no diagnostic test is precise enough to detect only cancers that will become life-threatening. But this article, and the new German S3 clinical practice guideline it's based on, shows how individualized, highly precise early detection can at least limit overdiagnosis and the overtreatment that follows it.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThis is a narrative review article, meaning the authors synthesized findings from the medical literature to provide a comprehensive overview. It is based on the systematic literature searches that were carried out to update the S3 clinical practice guideline on prostate cancer (AWMF registration number 043–022OL) for 2025.\u003c\/p\u003e\n\n\u003cp\u003eThe research team conducted \u003cstrong\u003e11 systematic literature searches\u003c\/strong\u003e covering the years 2020–2024, using the Medline and Cochrane databases. Data were extracted and evidence was evaluated according to the sign-grading system, a standardized method for rating the quality of scientific evidence.\u003c\/p\u003e\n\n\u003cp\u003eThe authors represent multiple German academic institutions, including the Heinrich-Heine University Medical Faculty in Düsseldorf, the German Cancer Research Center (DKFZ) in Heidelberg, University Hospital Jena, the University Medical Center Schleswig-Holstein in Lübeck, the University Hospital Bonn, and the University Hospital Ulm.\u003c\/p\u003e\n\n\u003ch2 id=\"early-detection\"\u003eRisk-Adapted Early Detection: The New PSA Strategy\u003c\/h2\u003e\n\n\u003cp\u003eThe biggest change in the new guidelines is a move away from \"one-size-fits-all\" annual screening toward a personalized, risk-adapted approach. Here's how it works:\u003c\/p\u003e\n\n\u003cp\u003eIf a man chooses to pursue early detection — and the advantages and disadvantages should be openly discussed with a doctor first — the process should begin at \u003cstrong\u003eage 45\u003c\/strong\u003e with a baseline measurement of \u003cstrong\u003eprostate-specific antigen (PSA)\u003c\/strong\u003e. PSA is a protein (specifically, a serine protease) produced by prostate cells that helps liquefy ejaculate. PSA levels rise when prostate cells are damaged, whether from prostatitis (inflammation), trauma (such as cycling or digital rectal examinations), or prostate cancer.\u003c\/p\u003e\n\n\u003cp\u003eAge 45 was also recommended in the past as a starting point, but the reasoning has changed. The key insight: with a baseline PSA value at this young age, most men can be spared the previously recommended annual early detection tests for at least five years. This matters because less frequent testing lowers both the number of \u003cstrong\u003efalse-positive findings\u003c\/strong\u003e (abnormal PSA levels without any cancer on follow-up tests) and the number of \u003cstrong\u003eoverdiagnoses\u003c\/strong\u003e (detecting a cancer that would never have caused harm).\u003c\/p\u003e\n\n\u003cp\u003eAt age 45–50, the detection rate of clinically relevant prostate cancer — defined by a grading group (GG) of 2–5 in the International Society of Urological Pathology (ISUP) classification — is just \u003cstrong\u003e0.2–0.4%\u003c\/strong\u003e. These relatively low prevalence figures come from the PROBASE study and the first round of the Swedish OPT implementation study.\u003c\/p\u003e\n\n\u003cp\u003eHere is how the baseline PSA value determines the recommended follow-up:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBelow 1.5 ng\/mL\u003c\/strong\u003e — Low risk: no further PSA testing needed for at least 5 years. This applies to \u003cstrong\u003e89% of men aged 45\u003c\/strong\u003e and \u003cstrong\u003e82% of men aged 50\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eBetween 1.5 and 3.0 ng\/mL\u003c\/strong\u003e — Intermediate risk: biennial (every 2 years) follow-up testing is recommended.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e3.0 ng\/mL or above (confirmed)\u003c\/strong\u003e — High risk: further evaluation is needed. Prostate cancer is found in \u003cstrong\u003e25–30%\u003c\/strong\u003e of these patients.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFor high-risk men, the next steps are confirmation of the PSA level within three months and a full risk assessment. If the PSA is still above 3 ng\/mL and cannot be explained by an enlarged prostate gland, acute inflammation, or other known causes, an \u003cstrong\u003eMRI of the prostate\u003c\/strong\u003e is recommended. These initial diagnostic steps eliminate the need for invasive biopsy in half of men with an initially abnormal PSA level.\u003c\/p\u003e\n\n\u003cp\u003eA baseline PSA measurement at age 45–50 has another powerful type of predictive value: it can predict the \u003cstrong\u003elifelong risk of developing metastatic prostate cancer\u003c\/strong\u003e. This predictive potential is highest at age 45–50 because men at this age have not yet developed age-related benign prostatic enlargement, making the PSA value a cleaner \"baseline\" measurement.\u003c\/p\u003e\n\n\u003cp\u003eOne of the major reasons for overdiagnosis and overtreatment in Germany is self-initiated testing at the wrong age. According to data from AOK (a German statutory health-insurance carrier) for 2022, most men undergo cancer screening for the first time only when they are already over \u003cstrong\u003e75 years old\u003c\/strong\u003e — probably in combination with a PSA test. Only \u003cstrong\u003e13%\u003c\/strong\u003e undergo their first test at the ideal diagnostic age of 45–50.\u003c\/p\u003e\n\n\u003cp\u003eMen with a suggestive family history — defined as one first-degree relative (brother or father) diagnosed with prostate cancer before age 60, or more than one first-degree relative with prostate cancer at any age — are offered the same early-detection strategy. Men with a genetic predisposition (such as pathogenic variants of the BRCA2 gene or the Lynch-syndrome-associated genes MSH2 and MSH6) should begin PSA-based screening from \u003cstrong\u003eage 40\u003c\/strong\u003e. Smoking is not considered a risk factor for prostate cancer.\u003c\/p\u003e\n\n\u003cp\u003eHere are the benefits and drawbacks of PSA-based screening, according to the guideline's evidence review:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAdvantages:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eLowers the probability of dying from prostate cancer: approximately \u003cstrong\u003e3 out of 1,000 men screened\u003c\/strong\u003e do not die of prostate cancer.\u003c\/li\u003e\n  \u003cli\u003eLowers the probability of developing metastatic prostate cancer: approximately \u003cstrong\u003e4 out of 1,000 men screened\u003c\/strong\u003e do not develop metastases.\u003c\/li\u003e\n  \u003cli\u003eReduces the need for frequent testing: \u003cstrong\u003e9 out of 10 men aged 45\u003c\/strong\u003e have a PSA below 1.5 ng\/mL and need no further testing for 5 years.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eDisadvantages:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePsychological stress from diagnostic testing for men with early-detected but non-life-threatening tumors.\u003c\/li\u003e\n  \u003cli\u003eOverdiagnosis: detection of cancer in 14 men to prevent one death, with a risk of overtreatment (surgery or radiotherapy for tumors that would never become life-threatening if left untreated).\u003c\/li\u003e\n  \u003cli\u003eUnnecessary diagnostic testing if the baseline PSA level is elevated with no other evidence of tumor.\u003c\/li\u003e\n  \u003cli\u003eFalse-positive findings: \u003cstrong\u003e3 out of 10 MRIs\u003c\/strong\u003e show normal findings; \u003cstrong\u003e3 out of 4 biopsies\u003c\/strong\u003e after elevated PSA levels show no tumor; \u003cstrong\u003e1 out of 4 biopsies\u003c\/strong\u003e after abnormal MRI show no tumor.\u003c\/li\u003e\n  \u003cli\u003eLow probability of a falsely negative (normal) PSA baseline value despite a real, clinically relevant tumor: false negative rate of \u003cstrong\u003e0.7 per 1,000\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eFrequent repetition of PSA tests needed in \u003cstrong\u003e1 out of 10 men\u003c\/strong\u003e with a baseline PSA of 1.5–3 ng\/mL (every two years).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"dre\"\u003eDigital Rectal Examination: What Has Changed\u003c\/h2\u003e\n\n\u003cp\u003eFor over 50 years, the digital rectal examination (DRE) has been part of the annual cancer screening recommended by German statutory health insurance carriers. That is no longer the case.\u003c\/p\u003e\n\n\u003cp\u003eThe reason is straightforward: DRE's sensitivity in early detection of prostate cancer has been shown to be \u003cstrong\u003einsufficient at just 5%\u003c\/strong\u003e. This means that DRE alone misses the vast majority of prostate cancers. The updated guidelines no longer recommend DRE for the early detection of prostate cancer.\u003c\/p\u003e\n\n\u003cp\u003eInstead, the focus is on PSA testing combined with MRI when indicated — a far more accurate approach.\u003c\/p\u003e\n\n\u003ch2 id=\"psa-mri\"\u003eThe New PSA-MRI Diagnostic Algorithm\u003c\/h2\u003e\n\n\u003cp\u003eThere is now an international consensus that any man of any age with a life expectancy of \u003cstrong\u003e10 years or more\u003c\/strong\u003e and a PSA level of \u003cstrong\u003e3 ng\/mL or higher\u003c\/strong\u003e should undergo diagnostic testing for prostate cancer. Life expectancy can be derived from the physician's estimate or from the gait speed table of Studenski et al. (based on mean walking speed over a distance of 6 meters).\u003c\/p\u003e\n\n\u003cp\u003eHowever, the process looks very different now. Before any invasive testing, patients should first undergo confirmation of PSA and a risk assessment that considers all factors that might elevate PSA — earlier diagnostic examinations, prostate size, inflammation, trauma, family history, and ethnicity. \u003cstrong\u003eOnline risk calculators\u003c\/strong\u003e (such as ERSPC or Cancer Research UK) are available for objective risk assessment.\u003c\/p\u003e\n\n\u003cp\u003eIf the calculators suggest an increased risk of prostate cancer (for example, a risk greater than 10% with the ERSPC No. 2 risk calculator), the next step is an \u003cstrong\u003eMRI of the prostate\u003c\/strong\u003e — not an immediate biopsy, as was previously recommended. This is the heart of the new \u003cstrong\u003e\"PSA-MRI algorithm.\"\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eWhy the change? Multiple randomized trials, primarily in prostate screening settings, have shown that this algorithm \u003cstrong\u003eeliminates the need for up to 70% of prostate biopsies\u003c\/strong\u003e. That's a massive reduction in invasive procedures.\u003c\/p\u003e\n\n\u003cp\u003eThe quality of the MRI and the expertise of the radiologist interpreting it are crucial. The new S3 guideline recommends that prostate MRI be performed according to current quality standards, with interpretation by a radiologist who is specially trained and \u003cstrong\u003ecertified in prostate MRI\u003c\/strong\u003e (a Q2 special certificate from the German Society of Radiology).\u003c\/p\u003e\n\n\u003cp\u003eThe MRI findings guide whether a biopsy is performed. The guideline specifies precisely:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eA so-called \u003cstrong\u003eMRI-ultrasound fusion biopsy\u003c\/strong\u003e is indicated when suspicion of prostate cancer on MRI is rated \u003cstrong\u003ePI-RADS (Prostate Imaging – Reporting and Data System) 4 or 5\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eBiopsy may also be considered at \u003cstrong\u003ePI-RADS 3\u003c\/strong\u003e if the patient is at high individual risk — for instance, when the \u003cstrong\u003ePSA density\u003c\/strong\u003e (the PSA level in ng\/mL divided by the prostate volume in mL) is greater than \u003cstrong\u003e0.15\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003ePI-RADS 1–2 lesions should \u003cstrong\u003enot\u003c\/strong\u003e be biopsied.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis targeted approach increases the tumor detection rate for clinically relevant prostate cancer in screening studies to \u003cstrong\u003enearly 50%\u003c\/strong\u003e. The rationale is to avoid unnecessary biopsies of clinically indolent carcinomas (ISUP GG 1) while catching the dangerous cancers. This strategy is backed by high-level evidence from multiple randomized trials.\u003c\/p\u003e\n\n\u003cp\u003eTo put the improved accuracy in perspective: with modern MRI-guided biopsy techniques, the \u003cstrong\u003epositive predictive value\u003c\/strong\u003e of an elevated PSA level rises to \u003cstrong\u003e42%\u003c\/strong\u003e — meaning that when a biopsy is performed after an abnormal MRI, cancer is found nearly half the time. This includes approximately 16% clinically indolent carcinomas in ISUP grade group 1 — those harmless tumors that wouldn't have caused problems. In men aged 55 to 69 with an elevated PSA level, traditional biopsy (without MRI guidance) finds cancer in only about \u003cstrong\u003e25%\u003c\/strong\u003e of cases.\u003c\/p\u003e\n\n\u003ch2 id=\"biopsy\"\u003eProstate Biopsy Techniques\u003c\/h2\u003e\n\n\u003cp\u003eWhen a biopsy is needed, the guideline offers some flexibility. Based on multiple randomized trials, both \u003cstrong\u003eperineal\u003c\/strong\u003e and \u003cstrong\u003etransrectal\u003c\/strong\u003e fusion biopsies can be recommended. There is an important caveat: transrectal biopsies should only be performed with \u003cstrong\u003eantibiotic protection\u003c\/strong\u003e to prevent infection. Both types of biopsy can be performed under either local or general anesthesia.\u003c\/p\u003e\n\n\u003cp\u003eThe choice of approach can be individualized based on patient anatomy, risk factors, and physician expertise.\u003c\/p\u003e\n\n\u003ch2 id=\"psma-pet\"\u003ePSMA-PET\/CT Imaging\u003c\/h2\u003e\n\n\u003cp\u003eA newer imaging tool called \u003cstrong\u003ePSMA-PET\/CT\u003c\/strong\u003e (positron emission tomography with prostate-specific membrane antigen as the target molecule) is gaining an important role. In this scan, a radioactive tracer targets PSMA, a protein found on prostate cancer cells, making even small areas of cancer visible on the scan.\u003c\/p\u003e\n\n\u003cp\u003eInitial evidence suggests PSMA-PET\/CT can provide valuable information during primary diagnostic testing, including information about how aggressive the cancer is (its ISUP grade group). The new guideline recommends PSMA-PET\/CT primarily to rule out \u003cstrong\u003elymph node and distant metastases\u003c\/strong\u003e in locally advanced prostate cancer — defined by ISUP grade group 3 or higher, stage cT3\/cT4, or PSA above 20 ng\/mL.\u003c\/p\u003e\n\n\u003cp\u003eThe evidence for this is strong. In randomized trials, PSMA-PET\/CT was found to be \u003cstrong\u003esignificantly superior to conventional imaging\u003c\/strong\u003e (computed tomography [CT] and bone scintigraphy). The accuracy of staging for lymph node metastases was:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e92%\u003c\/strong\u003e with PSMA-PET\/CT (confidence interval 88–95%)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e65%\u003c\/strong\u003e with conventional staging using CT and bone scintigraphy (confidence interval 60–69%)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThis difference was highly statistically significant (p \u0026lt; 0.0001), meaning there is virtually no chance it was due to random variation.\u003c\/p\u003e\n\n\u003cp\u003eWhy does this matter? Detecting lymph node or distant metastases has major therapeutic consequences. When cancer has already spread, local therapy alone (surgery or radiation to the prostate) is no longer sufficient — systemic treatment is needed instead.\u003c\/p\u003e\n\n\u003ch2 id=\"genetic\"\u003eGenetic Counseling and Testing\u003c\/h2\u003e\n\n\u003cp\u003eA new recommendation in the S3 guideline: genetic counseling and the offer of \u003cstrong\u003egermline testing\u003c\/strong\u003e (testing the DNA you inherited from your parents) should be offered to \u003cstrong\u003eall patients with metastatic prostate cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe background for this recommendation is the high prevalence — \u003cstrong\u003egreater than 10%\u003c\/strong\u003e — of pathogenic variants in DNA repair genes among these patients. Knowing about these genetic changes can matter for treatment decisions, especially for newer targeted therapies.\u003c\/p\u003e\n\n\u003ch2 id=\"treatment\"\u003eTreatment of Localized Prostate Cancer\u003c\/h2\u003e\n\n\u003cp\u003eApproximately \u003cstrong\u003e68% of prostate cancer cases\u003c\/strong\u003e are localized and non-metastatic (UICC stages I and II, meaning T1-T2c N0 M0) at the time of initial diagnosis. This is the group where treatment decisions are most nuanced.\u003c\/p\u003e\n\n\u003cp\u003eProstate cancer is classified into different ISUP grade groups after biopsy, based on the Gleason score (a measure of how abnormal the cancer cells look under the microscope). These groups define clinical risk categories, each with its own risk of mortality. The most commonly used and best-validated classification is the \u003cstrong\u003eNCCN (National Comprehensive Cancer Network)\u003c\/strong\u003e system, though the older D'Amico risk classification is still used in some places. The new subdivision of the intermediate-risk group has important implications for treatment.\u003c\/p\u003e\n\n\u003cp\u003eThe single most important study underpinning the new treatment recommendations is the British \u003cstrong\u003eProtecT trial\u003c\/strong\u003e, whose 15-year results were published in 2023. This landmark randomized trial compared the classic forms of treatment:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eRadical prostatectomy (surgical removal of the prostate)\u003c\/li\u003e\n  \u003cli\u003eRadiotherapy (radiation therapy)\u003c\/li\u003e\n  \u003cli\u003eActive monitoring (close observation with treatment only if needed)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe headline finding after 15 years of follow-up: there was \u003cstrong\u003eno difference in cancer-specific survival\u003c\/strong\u003e among the three approaches — survival was \u003cstrong\u003egreater than 97% in each case\u003c\/strong\u003e. In other words, the vast majority of men with localized prostate cancer did not die from their cancer regardless of which approach they chose.\u003c\/p\u003e\n\n\u003cp\u003eThis means patients with localized prostate cancer must be informed \u003cstrong\u003eneutrally\u003c\/strong\u003e by urologists and radiation oncologists about all three treatment options, with due consideration of their individual health status (comorbidity) and life expectancy. The analysis implies that low-risk tumors should be managed with active surveillance, as recommended in the new S3 guideline.\u003c\/p\u003e\n\n\u003ch2 id=\"active-surveillance\"\u003eActive Surveillance: Monitoring Instead of Surgery\u003c\/h2\u003e\n\n\u003cp\u003eActive surveillance is a strategy of close monitoring rather than immediate treatment. Patients in the NCCN \u003cstrong\u003elow-risk\u003c\/strong\u003e and \u003cstrong\u003every-low-risk\u003c\/strong\u003e groups make up approximately \u003cstrong\u003ehalf of all patients with localized prostate cancer\u003c\/strong\u003e, and they can be managed with active surveillance instead of surgery or radiation.\u003c\/p\u003e\n\n\u003cp\u003eA significant novelty in the German guideline: a defined group of patients at \u003cstrong\u003e\"favorable intermediate risk\"\u003c\/strong\u003e is also considered appropriate for active surveillance. This decision is based on large-scale histopathological studies of prostatectomy specimens (prostates removed during surgery), which showed a clear correlation between the frequency of \u003cstrong\u003eGleason pattern 4\u003c\/strong\u003e (out of 5) and the PSA recurrence rate after radical prostatectomy. Patients with ISUP grade group 2 prostate cancer who have only a small amount of Gleason pattern 4 can also be managed primarily with active surveillance. In practice, this means less than 25% Gleason pattern 4 without cribriform or intraductal growth patterns.\u003c\/p\u003e\n\n\u003cp\u003eKey recommendations for active surveillance:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAll patients with low-risk prostate cancer (ISUP GG 1)\u003c\/strong\u003e should primarily undergo active surveillance. Neither surgery nor radiotherapy is recommended for these patients.\u003c\/li\u003e\n  \u003cli\u003eActive surveillance is recommended only with a prostate MRI that meets current quality criteria and an MRI-guided biopsy, to avoid misclassification.\u003c\/li\u003e\n  \u003cli\u003eDuring active surveillance, PSA should be checked every \u003cstrong\u003e3 months\u003c\/strong\u003e (for ISUP GG 2) or every \u003cstrong\u003e6 months\u003c\/strong\u003e (for ISUP GG 1) for the first two years.\u003c\/li\u003e\n  \u003cli\u003eAn MRI-guided \u003cstrong\u003ere-biopsy\u003c\/strong\u003e is recommended at \u003cstrong\u003e12–18 months\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA critical distinction: active surveillance should be discontinued in favor of surgery or radiotherapy in the event of \u003cstrong\u003ehistological progression\u003c\/strong\u003e (worsening of the cancer grade on biopsy) — but NOT based on a PSA increase alone. Purely MRI-guided active surveillance without re-biopsy is possible but has not yet been sufficiently evaluated to be recommended as standard practice.\u003c\/p\u003e\n\n\u003ch2 id=\"surgery-radiation\"\u003eSurgery and Radiation Therapy\u003c\/h2\u003e\n\n\u003cp\u003eWhen treatment is needed — for men with higher-risk cancers or those who prefer definitive treatment — the guideline provides specific recommendations:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRadical prostatectomy (RP)\u003c\/strong\u003e is recommended for patients with localized prostate cancer who require treatment. It remains a cornerstone of definitive therapy.\u003c\/p\u003e\n\n\u003cp\u003eFor patients who experience \u003cstrong\u003ebiochemical recurrence\u003c\/strong\u003e (a rising PSA after surgery), the approach depends on the risk profile:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eFor patients with a \u003cstrong\u003ehigh-risk profile\u003c\/strong\u003e: \u003cstrong\u003edelayed percutaneous salvage radiotherapy\u003c\/strong\u003e is recommended if biochemical recurrence from the nadir (PSA below the detection limit) is detected after surgery.\u003c\/li\u003e\n  \u003cli\u003eFor patients with \u003cstrong\u003ebiochemical recurrence and a favorable risk profile\u003c\/strong\u003e (PSA doubling time greater than 12 months, ISUP GG less than 4): \u003cstrong\u003ewatchful waiting\u003c\/strong\u003e is an acceptable approach.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePSMA-PET\/CT\u003c\/strong\u003e examinations may be useful if PSA levels rise above \u003cstrong\u003e0.2 ng\/mL\u003c\/strong\u003e to locate the recurrence and assist in treatment planning.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePrimary curative radiation therapy\u003c\/strong\u003e should be delivered using \u003cstrong\u003eintensity-modulated percutaneous radiotherapy (IMRT)\u003c\/strong\u003e with \u003cstrong\u003eimage guidance (IGRT)\u003c\/strong\u003e — meaning the radiation is shaped precisely to the tumor and its position is verified at each treatment session. The standard dose is at least \u003cstrong\u003e74 Gy to 80 Gy\u003c\/strong\u003e in normofractionated form (standard daily doses).\u003c\/p\u003e\n\n\u003cp\u003eFor localized intermediate-risk and localized high-risk prostate cancer, either \u003cstrong\u003emoderate hypofractionation\u003c\/strong\u003e (for example, treatment over four weeks instead of eight) or normofractionated radiotherapy is indicated. The shorter course is more convenient for patients and has been shown to be equally effective.\u003c\/p\u003e\n\n\u003ch2 id=\"implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThe shift described in this article represents a fundamental change in prostate cancer care. For patients, the practical implications are substantial:\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFewer unnecessary tests and procedures.\u003c\/strong\u003e The old model had men getting annual PSA tests indefinitely. The new model means a single baseline PSA at age 45 tells you a lot about your personal risk. Most men (about 9 out of 10) will need no further testing for 5 years. When PSA is elevated, the routine next step is no longer an immediate biopsy — it's an MRI, which eliminates the need for up to 70% of biopsies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eMore accurate detection.\u003c\/strong\u003e MRI-guided fusion biopsy nearly doubles the chance that a biopsy, when performed, will find a real, clinically significant cancer (42% positive predictive value compared to about 25% for traditional biopsy). Fewer men will go through the discomfort and anxiety of a biopsy that finds nothing — or, worse, finds a harmless cancer that leads to unnecessary treatment.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLess overtreatment.\u003c\/strong\u003e The ProtecT trial's 15-year results provide powerful reassurance: for localized prostate cancer, cancer-specific survival exceeds 97% regardless of whether men choose surgery, radiation, or active monitoring. Half of men with localized prostate cancer are now candidates for active surveillance, avoiding the side effects of surgery and radiation (such as incontinence and erectile dysfunction) without compromising their survival.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBetter staging for high-risk disease.\u003c\/strong\u003e PSMA-PET\/CT can detect lymph node and distant metastases far more accurately than older imaging methods (92% vs 65% accuracy), ensuring that men who actually need systemic treatment get it, while those with truly localized disease aren't over-treated.\u003c\/p\u003e\n\n\u003cp\u003eThe authors note that patients can be expected to \u003cstrong\u003ebenefit greatly\u003c\/strong\u003e from the new PSA-MRI algorithm. It eliminates unnecessary diagnostic testing and treatment while enabling necessary treatment to be initiated earlier — and therefore with fewer side effects.\u003c\/p\u003e\n\n\u003cp\u003eHowever, there is a significant challenge ahead. The need for high-quality diagnostic testing, including MRI with broad geographic coverage, will be a major challenge to the health care system — especially regarding accessibility. Not every community will automatically have access to Q2-certified prostate MRI.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\n\u003cp\u003eThis article is a narrative review, not a new clinical trial. It synthesizes existing evidence, which means its conclusions depend on the quality of the underlying studies. Important limitations to keep in mind:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003eThe recommendations primarily reflect the German health care system, where the guideline was developed. Some recommendations (such as specific PSA thresholds and screening intervals) may not translate perfectly to other countries with different health care structures.\u003c\/li\u003e\n  \u003cli\u003eThe ProtecT trial, while landmark, enrolled a specific population and follow-up of 15 years — while prostate cancer can be slow-growing, longer-term differences between treatment approaches could emerge over 20–25 years.\u003c\/li\u003e\n  \u003cli\u003eActive surveillance protocols vary between health systems, and the optimal monitoring intensity continues to evolve. Pure MRI-guided surveillance without re-biopsy hasn't been fully validated yet.\u003c\/li\u003e\n  \u003cli\u003ePSMA-PET\/CT data, while compelling for staging accuracy, represents \"initial evidence\" for some uses in primary diagnostics. Long-term outcome data showing that PSMA-PET\/CT changes survival are still accumulating.\u003c\/li\u003e\n  \u003cli\u003eOverdiagnosis cannot be completely avoided — no diagnostic test can perfectly predict which cancers will become life-threatening. The strategies described reduce overdiagnosis but don't eliminate it.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\n\u003cp\u003eBased on the guideline changes described in this article, here is what men should consider discussing with their doctors:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStart early detection at age 45.\u003c\/strong\u003e If you're in the 45–50 age range and choose to be screened, request a baseline PSA test rather than waiting until later decades, when results are harder to interpret.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your baseline PSA number.\u003c\/strong\u003e A value below 1.5 ng\/mL is reassuring — you likely need no repeat testing for 5 years. Values of 1.5–3 ng\/mL mean testing every 2 years. Values above 3 ng\/mL require confirmation and a full urological risk assessment.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't panic over an elevated PSA.\u003c\/strong\u003e Remember: 3 out of 4 biopsies done after an elevated PSA alone show no cancer. The new approach uses MRI before biopsy, avoiding invasive procedures in half of men with elevated PSA.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about the quality of your MRI.\u003c\/strong\u003e If you need a prostate MRI, ask whether the radiologist is specially certified (Q2 special certificate) and whether the scanner meets current quality standards. This significantly affects accuracy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf diagnosed with low-risk prostate cancer, consider active surveillance.\u003c\/strong\u003e The evidence is clear that most low-risk cancers don't threaten your life. All patients with ISUP grade group 1 should primarily undergo active surveillance rather than immediate surgery or radiation.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have intermediate-risk cancer, ask whether you qualify for \"favorable intermediate risk\" active surveillance.\u003c\/strong\u003e If you have ISUP grade group 2 with less than 25% Gleason pattern 4 and no cribriform or intraductal growth patterns, monitoring may be a valid option.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMake treatment decisions based on the full picture.\u003c\/strong\u003e The ProtecT trial shows no difference in cancer-specific survival between surgery, radiation, and active monitoring at 15 years. Weigh side effects, your overall health, and your preferences — not just fear of the diagnosis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIf you have high-risk or metastatic prostate cancer, ask about genetic testing.\u003c\/strong\u003e More than 10% of men with metastatic disease carry pathogenic variants in DNA repair genes, which may affect treatment options.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't start screening at age 75+.\u003c\/strong\u003e Most men currently have their first screening after age 75, which is the wrong time — it leads to overdiagnosis of harmless tumors and overtreatment. If you're older, discuss whether screening is appropriate with your doctor based on your life expectancy.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhy should I have my first PSA test at age 45?\u003c\/h3\u003e\n\u003cp\u003eA baseline PSA at age 45 helps predict your lifelong risk of metastatic prostate cancer. Most men (about 9 out of 10) have a PSA below 1.5 ng\/mL and need no further testing for at least 5 years. This personalized approach reduces unnecessary tests and overdiagnosis compared with annual screening.\u003c\/p\u003e\n\u003ch3\u003eWhat does my PSA number mean after the baseline test?\u003c\/h3\u003e\n\u003cp\u003eA PSA below 1.5 ng\/mL means low risk and no repeat testing for at least 5 years. A PSA between 1.5 and 3.0 ng\/mL means intermediate risk and testing every 2 years. A confirmed PSA of 3.0 ng\/mL or above means high risk, and your doctor will recommend MRI to decide if a biopsy is needed.\u003c\/p\u003e\n\u003ch3\u003eWhy is a digital rectal exam no longer recommended for prostate cancer screening?\u003c\/h3\u003e\n\u003cp\u003eThe digital rectal exam (DRE) has a sensitivity of only 5%, meaning it misses the vast majority of prostate cancers. New guidelines recommend PSA testing combined with MRI when indicated, which is far more accurate. DRE is no longer part of routine early detection for prostate cancer.\u003c\/p\u003e\n\u003ch3\u003eIf my PSA is elevated, do I need a biopsy right away?\u003c\/h3\u003e\n\u003cp\u003eNo. First, your PSA is confirmed and your overall risk is assessed using factors like prostate size, inflammation, and family history. If risk is increased, you undergo a prostate MRI. An MRI-ultrasound fusion biopsy is indicated only for findings rated PI-RADS 4 or 5. This approach avoids up to 70% of unnecessary biopsies.\u003c\/p\u003e\n\u003ch3\u003eWhat is active surveillance and can I choose it instead of surgery or radiation?\u003c\/h3\u003e\n\u003cp\u003eActive surveillance means closely monitoring low-risk prostate cancer instead of treating it immediately. All patients with low-risk cancer (ISUP grade group 1) should primarily have active surveillance. Even some favorable intermediate-risk patients (less than 25% Gleason pattern 4) can be monitored. PSA is checked regularly and MRI-guided re-biopsy is recommended at 12–18 months.\u003c\/p\u003e\n\u003ch3\u003eDoes treatment choice affect survival for localized prostate cancer?\u003c\/h3\u003e\n\u003cp\u003eIn the ProtecT trial, after 15 years, cancer-specific survival exceeded 97% whether men chose surgery, radiation, or active monitoring. There was no difference in cancer-specific death among the three approaches. This means patients should be informed neutrally about all options, weighing side effects and personal preferences.\u003c\/p\u003e\n\u003ch3\u003eShould I have genetic testing if I have prostate cancer?\u003c\/h3\u003e\n\u003cp\u003eGenetic counseling and germline testing are recommended for all patients with metastatic prostate cancer. More than 10% of these men carry pathogenic variants in DNA repair genes. Knowing about these changes can influence treatment decisions, especially regarding newer targeted therapies. Discuss this with your doctor.\u003c\/p\u003e\n\u003ch3\u003eShould I get a second opinion before deciding between active surveillance and surgery or radiation for localized prostate cancer?\u003c\/h3\u003e\n\u003cp\u003eYes, a second opinion is valuable because the ProtecT trial showed that for localized prostate cancer, cancer-specific survival exceeds 97% whether you choose surgery, radiation, or active monitoring. The new guideline recommends that low-risk (ISUP grade group 1) cancers be managed with active surveillance, and some favorable intermediate-risk cases may also qualify. A second opinion can confirm your risk group and ensure you are not over-treated. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article:\u003c\/strong\u003e \"The Early Detection, Diagnostic Evaluation, and Local Treatment of Prostate Cancer: A Paradigm Shift\"\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e Deutsches Ärzteblatt International | Dtsch Arztebl Int 2025; 122: 420–6\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3238\/arztebl.m2025.0099\u003c\/p\u003e\n\n\u003cp\u003eThis article was based on the systematic literature searches carried out for the 2025 update of the German S3 clinical practice guideline on prostate cancer (AWMF registration number 043–022OL).\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003eThis patient-friendly article is based on peer-reviewed research and is intended for educational purposes. It does not replace individualized medical advice. Always consult your physician about screening, diagnosis, and treatment decisions.\u003c\/em\u003e\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458814722204,"sku":null,"price":0.0,"currency_code":"JPY","in_stock":true}],"url":"https:\/\/diagnosticdetectives.tw\/products\/prostate-cancer-detection-and-treatment-a-new-approach-for-patients","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}